Labcorp Holdings Inc(LH) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | S&P 500 | P/E | 25.38 | EPS (ttm) | 12.09 | Insider Own | 0.4% | Shs Outstand | 80.9M | Perf Week | -7.45% |
| Market Cap | 24.89B | Forward P/E | 15.44 | EPS next Y | 8.36% | Insider Trans | -5.66% | Shs Float | 80.8M | Perf Month | -4.79% |
| Enterprise Value | 31.54B | PEG | 1.62 | EPS next Q | 4.65 | Inst Own | 101.28% | Short Float | 2.4% | Perf Quarter | 14.27% |
| Income | 1.00B | P/S | 1.74 | EPS this Y | 11.62% | Inst Trans | 0.24% | Short Ratio | 2.84 | Perf Half Y | 13.51% |
| Sales | 14.35B | P/B | 2.89 | EPS next 5Y | 9.5% | ROA | 5.48% | Short Interest | 1.94M | Perf YTD | 22.35% |
| Book/sh | 106.39 | P/C | 175.56 | EPS past 3/5Y | -9.18% -8.01% | ROE | 11.74% | 52W High | -10.19% ($341.80) | Perf Year | 12.46% |
| Cash/sh | 1.75 | P/FCF | 21.55 | Sales past 3/5Y | 5.55% -0.04% | ROIC | 6.6% | 52W Low | 25.54% ($244.52) | Perf 3Y | 50.98% |
| Dividend Est. | $2.95 (0.96%) | EV/EBITDA | 13.56 | EPS Y/Y TTM | 33.31% | Gross Margin | 26.82% | Volatility(W/M) | 2.14% 2.16% | Perf 5Y | 18.73% |
| Dividend TTM | 2.88 | EV/Sales | 2.2 | Sales Y/Y TTM | 6.41% | Oper. Margin | 11.35% | ATR (14) | 8 | Perf 10Y | 164.64% |
| Dividend Ex-Date | 2026/8/28 | Quick Ratio | 1.53 | EPS Q/Q | 28.47% | Profit Margin | 6.99% | RSI (14) | 35.5 | Recom | 1.76 |
| Dividend Gr. 3/5Y | 10.06% - | Current Ratio | 1.8 | Sales Q/Q | 5.78% | SMA20 | -6.61% ($328.69) | Beta | 0.87 | Target Price | $344.73 |
| Payout | 27.54% | Debt/Eq | 0.79 | Earnings | 2026/7/30 | SMA50 | -0.65% ($308.97) | Rel Volume | 1.84 | Prev Close | $321.1 |
| Employees | 71000 | LT Debt/Eq | 0.76 | EPS/Sales Surpr. | 4.41% 0.59% | SMA200 | 11.05% ($276.42) | Avg Volume(3M) | 0.68M | Price | $306.96 |
| IPO | 1988/7/7 | Option/Short | Yes/Yes | Trades | 21970 | Volume | 1,258,181 | Change | -4.4% |
Company
LH is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🔬 Labcorp Holdings (LH) is a global leading healthcare diagnostics company that provides comprehensive life sciences solutions worldwide, spanning from routine health diagnostics for individual patients to complex clinical trial support for pharmaceutical companies and next-generation drug development.
Over the past 1 year, roughly in the middle
10% below its 1-year high.
LH has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +11.6% this year.
Tap to view numbers
The price looks about right
Trading at 25.4 times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 2 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Long-term returns are close to the market
Would have changed by +51.0% if bought 5 years ago.
Tap to view numbers
The dividend is on the small side
Pays 0.96% annually in dividends.
Tap to view numbers
Ownership looks stable
Institutions hold 101.3%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
IHF 0.03%
ASLV 0.03%
STNC 0.03%
CAMX 0.03%
KNO 0.02%It ranks #4 in the industry
Based on market cap of $25B.
LH $25B PER 25.4
TMO $223B PER 32.5
DHR $141B PER 35.6
NTRA $47B PER -
FAQ
What kind of company is LH?
LH belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of LH?
The market cap of LH is approximately $24.9B, ranking 524 within its sector.
Does LH pay dividends?
LH has a dividend yield of approximately 0.96%, with an annual dividend of $2.95.
What is the P/E ratio of LH?
LH has a P/E ratio of approximately 25.4x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for LH?
LH has recorded a 52-week high of $341.80 and a low of $244.52.
